Avalyn Pharma Inc. Common Stock

AVLN

NASDAQHealthcareBiotechnology

在 GoAI 中打开

前收盘价

US$38.37

+US$1.24 · +3.34%

8月21日 16:00 ET

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

42/ 100

GoAI评分

Hold

Wait — insufficient conviction to act

估值

Expensive

动量

Weakening

情绪

Bullish

风险韧性

Elevated Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Lyn Baranowski
上市以来: 2026年4月30日
雇员: 55

市场位置

日内区间

当前US$38.37，

US$37.13US$39.68

52周区间

当前US$38.37，

US$24.15US$40.17

开盘价: US$37.13
前收盘价: US$37.13
成交量: 15.95万; 0.32× 平均值
平均成交量: 49.63万; 日均成交量
市值: 17.01亿 USD
贝塔: -1.13; 市场参考 1
50天平均值: US$31.0482; 高于平均水平+23.58%
200天平均值: US$29.9971; 高于平均水平+27.91%

财务数据

财务快照

估值与收益率

市盈率（TTM）: -29.74×
市净率（TTM）: 4.27×
市销率（TTM）: 0×
股息率: 0.00%

盈利能力和效率

毛利率: 0.00%
营业利润率: 0.00%
净利润率: 0.00%

财务健康

负债权益比: 0.04×

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$60.00

上涨空间 56.37%

过去 12 个月12个月预测最高：US$80.00平均的：US$60.00最低：US$51.00

AVLN 消息

globenewswire.com2026年8月12日

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory Society (ERS) Congress,…

阅读源码

globenewswire.com2026年6月17日

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

Company expects to report topline 12-month clinical results in the second half of 2027 Company expects to report topline 12-month clinical results in the second half of 2027

阅读源码

marketbeat.com2026年6月5日

Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead

Avalyn Pharma NASDAQ: AVLN executives outlined the company's inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position…

阅读源码

globenewswire.com2026年6月3日

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability…

阅读源码

globenewswire.com2026年5月27日

Avalyn to Participate in the Jefferies Global Healthcare Conference

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory…

阅读源码